Thomas Jefferson University

Jefferson Digital Commons
Department of Neurosurgery Faculty Papers

Department of Neurosurgery

12-2013

Review of cerebral aneurysm formation, growth, and rupture.
Nohra Chalouhi, MD
Thomas Jefferson University

Brian L Hoh
University of Florida, Gainesville

David Hasan
University of Iowa Hospitals and Clinics

Follow this and additional works at: https://jdc.jefferson.edu/neurosurgeryfp
Part of the Neurosciences Commons

Let us know how access to this document benefits you
Recommended Citation
Chalouhi, MD, Nohra; Hoh, Brian L; and Hasan, David, "Review of cerebral aneurysm formation,
growth, and rupture." (2013). Department of Neurosurgery Faculty Papers. Paper 59.
https://jdc.jefferson.edu/neurosurgeryfp/59
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Neurosurgery Faculty Papers by an authorized administrator of the
Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Review of Cerebral Aneurysm Formation, Growth, and Rupture
Nohra Chalouhi, Brian L. Hoh and David Hasan
Stroke. 2013;44:3613-3622; originally published online October 15, 2013;
doi: 10.1161/STROKEAHA.113.002390
Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://stroke.ahajournals.org/content/44/12/3613

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published
in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office.
Once the online version of the published article for which permission is being requested is located, click
Request Permissions in the middle column of the Web page under Services. Further information about this
process is available in the Permissions and Rights Question and Answer document.
Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints
Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org//subscriptions/

Downloaded from http://stroke.ahajournals.org/ at Thomas Jefferson Universi on June 17, 2014

Review of Cerebral Aneurysm Formation, Growth,
and Rupture
Nohra Chalouhi, MD; Brian L. Hoh, MD; David Hasan, MD

C

erebral aneurysms (CAs) occur in 3% to 5% of the general population and are characterized by localized structural deterioration of the arterial wall, with loss of the internal
elastic lamina and disruption of the media.1 The most dreaded
complication of CAs is rupture, the likelihood of which is
related to several modifiable and nonmodifiable risk factors.
Despite advances in surgical techniques and perioperative
management, the mortality and morbidity associated with
aneurysm rupture remain high.2 Current therapeutic options
are limited to invasive therapies, namely microsurgical clipping and endovascular treatment, both of which carry a nonnegligible risk of procedural morbidity.
In recent years, it has become obvious that CAs are not passively enlarging vascular structures but exhibit prominent features of inflammation and tissue degeneration. Other factors
mainly hemodynamic, genetic, hormonal, and environmental
may also play an important role. Knowledge of the pathogenic
pathways of CAs may pave the way for the development of
noninvasive therapies. The purpose of this review is to summarize the most relevant data on the molecular mechanisms,
genetics, and risk factors for aneurysm formation, growth, and
rupture. Although there are different forms of CAs, the present
discussion focuses on saccular aneurysms, which represent
the most common type of CAs and are also the most common
cause of subarachnoid hemorrhage (SAH).

Cerebral Aneurysms: an Inflammatory Disease
Increasing evidence points to inflammation as the leading factor in the pathogenesis of CAs. The inflammatory process is
initiated by a hemodynamic insult and leads to matrix metalloproteinases (MMPs)–mediated degradation of the extracellular
matrix and apoptosis of smooth muscle cells (SMCs), which
are the predominant matrix-synthesizing cells of the vascular
wall. These processes act in concert to weaken the arterial wall
progressively, resulting in dilatation, aneurysm formation, and
ultimately rupture (Figure; Table 1). The data supporting a
major role for inflammation in CA pathogenesis are strong and
derive from both experimental and human studies. The 2 main
constituents of the inflammatory response and the associated
degenerative response are macrophages and SMCs.

Macrophages are invariably noted in human aneurysm samples.3 The tissue-infiltrating macrophages not only release proinflammatory cytokines that lead to recruitment of additional
inflammatory cells, but also release MMPs that digest arterial
wall extracellular matrix and cause further damage via upregulation of other proteinases. As such, Aoki et al4 elegantly
demonstrated that the expression of macrophages and macrophage-derived MMPs was closely associated with aneurysm
growth, and that selective inhibition of these MMPs blocked
aneurysm progression. Likewise, macrophage-depleted mice
were found by Kanematsu et al5 to have a substantially lower
risk of developing CAs. Along similar lines, the inhibition of
monocyte chemoattractant protein-1 (MCP-1), a chemokine
regulating the migration and infiltration of macrophages,
halted CA formation in mice.6 In a comparative study of ruptured and unruptured human CAs, macrophage infiltration
was strongly associated with aneurysm rupture.7 Interestingly,
macrophages seem to be present in human CAs in 2 different
forms that exert opposite effects on inflammation.8 Whereas
the proinflammatory M1 cells and the anti-inflammatory M2
cells are present in equal proportion in unruptured aneurysms,
the balance shifts toward M1 cells in ruptured aneurysms,
suggesting a role for M1/M2 imbalance in the progression of
human CAs to rupture.8 Also, the critical role of macrophages
in CAs has allowed the development of targeted molecular
imaging for identifying rupture-prone aneurysms,9,10 and this
will be discussed in further detail below. Therapies targeting
macrophage activation and MMP release in aneurysm walls or
preventing the M1/M2 imbalance may potentially halt aneurysm formation and rupture.
SMCs play a pivotal role in the formation, progression, and
rupture of CAs. As discussed above, SMCs, mostly concentrated in the media, are the predominant matrix-synthesizing
cells of the vascular wall. The media provide structural integrity to the arterial wall, and the thinning of this layer contributes to aneurysm formation and rupture. Early in aneurysm
formation, SMCs migrate into the intima in response to endothelial injury and proliferate, producing myointimal hyperplasia.11 Subsequently, SMCs undergo phenotypic modulation
from a differentiated phenotype concerned with contraction
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Figure. Cerebral aneurysm (CA) formation and rupture. Aneurysm formation is initiated by hemodynamically triggered endothelial dysfunction. An inflammatory response implicating several cytokines and inflammatory mediators as well as macrophages, T cells, and mast
cells ensues. Concurrently, smooth muscle cells (SMCs) undergo phenotypic modulation to a proinflammatory phenotype. The inflammatory response in vessel wall leads to disruption of internal elastic lamina, extracellular matrix digestion, and aneurysm formation. Loss of
mural cells and further inflammation and vessel wall degeneration ultimately lead to CA rupture. bFGF indicates basic fibroblast growth
factor; COX2, cyclooxygenase-2; ECM, extracellular matrix; ICAM, intercellular adhesion molecule; IL, interleukin; MCP, monocyte chemoattractant protein; MMP, matrix metalloproteinase; NK, natural killer; NO, nitric oxide; PGD, prostaglandin D; PGE, prostaglandin E;
ROS, reactive oxygen species; TGF, transforming growth factor; TLR, toll-like receptor; TNF, tumor necrosis factor; VCAM, vascular cell
adhesion molecule; VEGF, vascular endothelial growth factor; and VSMC, vascular smooth muscle cell.
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Table 1. Inflammatory Pathways and Mediators Implicated in
CA Formation and Rupture
Pathway

Mediators

Endothelial dysfunction

IL-1β
NF-κB
Ets-1
MCP-1
Reactive oxygen species
Nitric oxide (NO), endothelial NO synthase,
inducible NO synthase
Angiotensin II
Phosphodiesterase-4
Prostaglandin E2
E selectin, P selectin, vascular cell adhesion
protein 1 (VCAM1), intercellular adhesion
molecule 1 (ICAM1)

Phenotypic modulation and
loss of SMCs

TNF-α
KLF-4
IL-1β
P47phox
MCP-1
MMPs
Adhesion molecules

Macrophages, M1/M2
imbalance, leukocyte
infiltration

MCP-1
NF-κB
Ets-1
MMPs
IL-1β
TNF-α
Normal T cell expressed and secreted
Monokine induced by γ-interferon
Interferon-γ–induced protein-10
Eotaxin
IL-8
IL-17

Vascular remodeling, cell
death

MMP and cathepsins
TNFα
IL-1β, IL-6
Toll-like receptor 4
Fas
NO
Complement
IgG, IgM
Basic fibroblast growth factor, transforming
growth factor α and β, and vascular
endothelial growth factor
Reactive oxygen species

IL-1β indicates interleukin 1β; KLF-4, Kruppel-like transcription factor 4;
MCP-1, monocyte chemoattractant protein-1; MMP, matrix metalloproteinase;
NF-κB, nuclear factor-κ B; SMC, smooth muscle cell; and TNFα, tumor
necrosis factor-α.

to a dedifferentiated phenotype, promoting inflammation and
matrix breakdown (downregulation of contractile genes, such
as myocardin, and upregulation of proinflammatory genes,
such as MMPs, MCP-1, vascular cell adhesion molecule 1,
and interleukins).12,13 Morphologically, modulated SMCs are
no longer arranged in tightly compacted bands but dissociate from each other to be transformed into spider-like cells
in aneurysm walls.14 The ability of these SMCs to synthesize
collagen is severely impaired. A late event commonly seen
in ruptured aneurysms is the loss of SMC with thinning of
the media.3 Guo et al15 found decreased SMC density and

a significant increase in the activity of caspases in ruptured
aneurysms compared with control vessels, whereas Sakaki
et al16 added that SMCs in the wall of ruptured aneurysms
were much more degenerated/apoptotic than those in the wall
of unruptured aneurysms. A series of in vitro and in vivo studies by the Jefferson group found that the phenotypic modulation of SMCs in CAs was induced by tumor necrosis factor-α
(TNF-α).17,18 Specifically, TNF-α inhibited the contractile
phenotype of SMCs and induced proinflammatory/matrixremodeling genes, namely MCP-1, MMPs, vascular cell adhesion molecule 1, and interleukin 1β (IL-1β).17 This process
was mediated by Kruppel-like transcription factor 4, a known
regulator of SMC differentiation. In a follow-up study, the
same group found that phenotypic modulation of SMCs was
reversed with a TNF-α inhibitor after aneurysm induction.18
Collectively, these data indicate that SMCs under the influence of inflammatory mediators, particularly TNF-α, promote
aneurysm formation, progression, and rupture.
Although best known for their role in allergy and anaphylaxis, mast cells seem to be involved in the pathophysiology
of CAs mostly through the release of various proinflammatory
cytokines. The number of mast cells is significantly increased
during CA formation, and their degranulation induces the
expression and activation of MMPs.19 Additionally, mast cell
degranulation inhibitors attenuate the inflammatory reaction
in aneurysm walls and block the progression of CAs in mice.19
Furthermore, Hasan et al8 found that mast cells are invariably
present in CA walls and were more prominently upregulated
in ruptured than in unruptured human CAs, suggesting a role
for mast cells in aneurysm rupture.
Several cytokines and inflammatory mediators are involved
in the pathogenesis of CAs. IL-1β and TNFα are the 2 most
studied cytokines in CAs. IL-1β is induced in the early stages
of CA formation in mice, and its expression promotes SMC
apoptosis and aneurysm progression.20 Additionally, IL-1β
inhibits collagen biosynthesis both at the transcriptional and
post-transcriptional levels, thus further contributing to the progression and weakening of CAs.21 TNF-α promotes the crucial
SMC phenotypic modulation in aneurysm walls and directly
activates MMPs while also reducing the expression of tissue
inhibitor of metalloproteinase-1.22 Moreover, Jayaraman et al23
demonstrated that TNF-α has a proapoptotic and proinflammatory action in CA walls through its downstream target FAS. In a
recent study, Starke et al24 highlighted the critical role of TNF-α
in both aneurysm formation and rupture. Specifically, they demonstrated that CA formation (through induced hypertension and
elastase injection) occurred in 81.8% of animals receiving only
vehicle as compared with only 25% of TNF-α knockout mice
and 33% of those treated with TNF-α inhibitor. Furthermore,
TNF-α knockout mice were >12× less likely to have aneurysm
rupture as compared with those receiving vehicle only.
Chemokines are chemoattractants for leukocytes that direct
them toward sites of tissue inflammation. Their contribution to
CA pathogenesis is recently being investigated. Chalouhi et al25
compared the concentrations of chemokines and other inflammatory molecules in blood samples drawn from the lumen of human
CAs of 16 patients with blood samples from the femoral arteries
of the same patients and found higher plasma concentrations of
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5 chemokines (MCP-1, regulated on activation, normal T cell
expressed and secreted [RANTES], monokine-induced-by-γinterferon, interferon-γ-induced protein-10, and Eotaxin) and
2 chemoattractant cytokines (interleukin 8 and interleukin 17)
in the lumen of CAs. These findings suggest that there may be
an active chemokine-driven recruitment of inflammatory cells
into the aneurysm wall. The findings match well with those of
Krischek et al26 who reported in a networked-based gene expression analysis of CA tissue that chemokines were among the most
significant canonical pathways involved in aneurysm tissue.
Thus, chemokines may be a central factor in the inflammatory
reaction in aneurysm walls, and this may open new therapeutic
perspectives in the treatment of CAs.
With regard to the role of complement in the inflammatory
response leading aneurysm formation, Tulamo et al27 found
the expression of membrane attack complex to be greater in
ruptured aneurysm samples as compared with unruptured
samples. Complement expression was also associated with
aneurysm wall degeneration and inflammatory cell infiltration. The same group later reported that activation of complement in CAs occurs primarily via the classical pathway.28
However, an explanation of how complement activation may
contribute to aneurysm formation remains to be determined.
Reactive oxygen species (ROS) may also have a role in
the pathogenesis of CAs.29 Aoki et al30 showed that ROSproducing genes were upregulated, and that ROS-eliminating
genes were suppressed in CAs in mice, which indicated that
overproduction of ROS occurred in aneurysm walls. Moreover,
both a free radical scavenger (edaravone) and the deletion of
ROS-producing gene (p47phox) effectively inhibited CA formation by suppressing inflammation in aneurysmal walls. In
a critical review of the literature on ROS, Starke et al29 found
that oxidative stress can induce important processes leading to
CA formation including direct endothelial injury, SMC phenotypic modulation and apoptosis, recruitment and invasion
of inflammatory cells through upregulation of chemotactic
cytokines and adhesion molecules, and MMPs activation.
Several studies have profiled gene expression in CAs, using
microarray or polymerase chain reaction techniques, in an
attempt to characterize the mechanisms underlying aneurysm
formation, growth, and rupture. Although the results were
somewhat heterogeneous across studies, alteration in expression genes related to the inflammatory and immune responses
as well as the extracellular matrix were frequently observed in
CAs and more so in ruptured than in unruptured aneurysms.
Aoki et al31 compared the gene expression profile between normal cerebral arteries and experimentally induced CAs in rats
and found upregulation of gene expression for MMPs, ROS,
growth factors, chemokines, complement, adhesion molecules,
and apoptosis in CAs. Kurki et al32 compared the whole-genome
expression profile of 11 ruptured and 8 unruptured CAs using
oligonucleotide microarrays and reported that response to turbulent blood flow, chemotaxis, leukocyte migration, oxidative
stress, vascular remodeling, and extracellular matrix degradation were significantly upregulated biological processes in ruptured aneurysms. Significantly enriched genes were toll-like
receptor signaling, nuclear factor-κB, hypoxia-inducible factor1A, and ETS transcription factor–binding sites. Conversely,

Pera et al33 examined transcription profiles in ruptured CAs,
unruptured CAs, and control middle meningeal arteries and
paradoxically found downregulation of genes involved with the
immune system and inflammation in ruptured samples. These
results suggested a protective role of inflammation against
aneurysm rupture. However, the study had limitations pertaining to sample size, baseline comparability, and extracerebral
control tissue. Overall, gene expression studies provide useful
data for understanding the pathophysiology of CAs; however,
differences in microarray technique, statistical analysis, control
tissue, type of aneurysm, and studied population make comparison across studies difficult.
Given the critical role of inflammation in aneurysm pathogenesis, several therapeutic strategies have been investigated
with overall mixed but promising results (Table 2).3 Perhaps
the most promising of all strategies has been acetylic acid
(ASA), more commonly referred to as aspirin. ASA exerts its
antiplatelet and anti-inflammatory actions by irreversible acetylation of cyclooxygenase-1 and -2, and possibly also through
the formation of nitric oxide radicals and the modulation of
inﬂammatory signaling pathways by the main ASA metabolite, salicylic acid. In a case–control study from patients
enrolled in the International Study of Unruptured Intracranial
Aneurysms, Hasan et al34 found that patients using aspirin
had a lower risk of hemorrhage than those who never used
aspirin. Building on this work, the same group reported that
ruptured aneurysms have higher immunohistochemical staining for cyclooxygenase-2 and microsomal prostaglandin E2
synthase 1, thus concluding that the protective effect of aspirin
against rupture of CAs is mediated in part by inhibition of
cyclooxygenase-2/microsomal prostaglandin E2 synthase 1.28
Indeed, in a trial comparing 5 patients treated with ASA and
5 other control patients, the expression of macrophages and
Table 2. Noninvasive Therapies for Preventing Formation,
Growth, or Rupture of Cerebral Aneurysms
Therapies Showing Efficacy

Therapies With No Effect
Statins (human studies)37

Aspirin (human studies)

34,36

Nuclear factor-κB decoy ODN (rats)

Valsartan (rats)39

Pravastatin, low dose (rats)40

Pravastatin, high dose induces
aneurysm formation (rats)40

Simvastatin (rats)41

Simvastatin (rats)40

Infliximab (TNF-α inhibitor; rats)24

Clodronate liposomes (deplete
circulating monocytes; rabbits)42

38

MMP inhibitor (Tolylsam; rats)4
MCP-1 inhibitor (7ND; rats)6
Phosphodiesterase-4 inhibitor
(Ibudilast; rats)43
Cathepsin inhibitor (NC-2300; rats)44
Mast cell degranulation
inhibitor (Tranilast, emedastine
difumarate; rats)19
Free radical scavenger
(Edaravone; rats)30
Doxycycline (MMPs inhibitor; rabbits)42
MCP-1 indicates monocyte chemoattractant protein-1; MMP, matrix metallo
proteinase; ODN, oligodeoxynucleotide; and TNF-α, tumor necrosis factor-α.
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inflammatory molecules in CAs after clipping was found to
be significantly decreased in the ASA group.35 Although this
study provided novel data that ASA may attenuate the inflammatory process in the walls of human CAs, larger studies with
long follow-up periods are needed to address whether ASA
also prevents aneurysmal SAH. Bringing confirmation to the
work of Hasan et al34 is a recently published study from Europe
that showed that chronic low dose aspirin therapy has a protective effect against SAH and does not increase the risk of intracerebral hemorrhage.36 Furthermore, there was a particularly
pronounced trend toward decreased risk of SAH among those
on long-term aspirin therapy (>3 years). Collectively, these
data suggest that aspirin may be a serious noninvasive strategy
for prevention of SAH. If the efficacy of aspirin is confirmed
in a randomized controlled trial, aspirin could potentially be
offered as a treatment for those patients in whom the risk of
invasive therapy exceeds the risk of aneurysm rupture. For
example, a 75-year-old man with a 5-mm CA would be a perfect candidate for aspirin treatment. Likewise, aspirin may
be used to decrease the risk of aneurysm rupture in patients
refusing any sort of invasive therapies or in countries where
invasive, specialized therapies are not available. The fact that
aspirin is an inexpensive and widely available and used drug
makes it an ideal candidate in this setting.
Besides ASA, statins have extensively been investigated
as possible therapeutic agents for CAs but the data have
been conflicting thus far. Although a lower dose of statins
(5 mg/kg per day) reduced endothelial damage and inhibited aneurysm formation in mice, higher doses (25–50 mg/kg
per day) facilitated aneurysm growth and promoted aneurysm
rupture.3 Further study will be needed to determine whether
statins may have a future role in the treatment of CAs. Despite
evidence for a potential role of angiotensin in the pathophysiology of CAs, angiotensin-receptor blockers have shown littleto-no efficacy in preventing aneurysm formation and growth.3

Hemodynamics, Endothelial Dysfunction, and CAs
Hemodynamic stress is the initiating factor for CA formation.3 This is best illustrated by the observation that CAs occur
at arterial junctions, bifurcations, or abrupt vascular angles
where excessive hemodynamic stresses are exerted on arterial walls. In a well-designed study, Meng et al45 created new
branch points in the carotid vasculature of 6 dogs and observed
destructive remodeling in the adjacent region of flow acceleration that resembled the initiation of an intracranial aneurysm,
characterized by disruption of the internal elastic lamina, loss
of medial SMCs, reduced proliferation of SMCs, and loss of
fibronectin. They concluded that a combination of high wall
shear stress (WSS) and a high gradient in WSS strongly predisposes to CA formation. The same group extended their
previous findings by demonstrating a correlation between the
degree of destructive remodeling accounting for internal elastic lamina loss, medial thinning, and luminal bulging with the
magnitude of WSS at arterial bifurcations.46
Although it is clear that high WSS drives CA formation,
the question of whether low or high WSS promotes aneurysm
progression and rupture remains unanswered. Whereas Cebral
et al47 found that high and concentrated WSS was associated

with aneurysm rupture, several computational fluid dynamic
studies have shown that the WSS at the tip or bleb of an aneurysm, where rupture most commonly occurs, is in fact low.48,49
It is thought that low WSS may induce apoptosis of endothelial cells, thus promoting the structural remodeling/fragility
of the aneurysm wall and ultimately leading to CA rupture.
In an attempt to reconcile the conflicting data, some authors
have proposed that low WSS may trigger the growth and rupture of large, atherosclerotic aneurysm phenotypes through
an inflammatory reaction, whereas high WSS may trigger the
growth and rupture of small or bleb aneurysm phenotypes
though a mural response (MMP production, mural cell apoptosis, medial thinning).50 However, the proposed mechanisms
remain purely speculative, and further investigation is needed
to answer this crucial question.
Endothelial dysfunction is a hallmark of CA biology. As
discussed above, endothelial dysfunction and vessel wall
inflammation and remodeling are directly triggered by WSS.
Kadirvel et al51 elegantly revealed endothelial cell loss and differential expression of biological markers of vascular remodeling namely MMPs in areas of low WSS in elastase-induced
saccular aneurysms. Likewise, Wang et al52 showed that WSS
induces endothelial dysfunction, as evidenced by the loss
endothelial nitric oxide synthase expression, and upregulation
of inflammatory markers in a canine model of CAs. Jamous
et al31 reported that endothelial cell injury induced by hemodynamic abnormalities was the earliest change in aneurysm
wall, followed by the formation of an inflammatory zone that
leads to proteolytic destruction of the vascular extracellular
matrix by MMP. Some investigators also suggest that the activation of nuclear factor-κ B in endothelial cells pursuant to
hemodynamic stress may be the earliest step in CA formation
because dramatic blockade of aneurysm formation was seen
after inhibition of nuclear factor-κ B in mice.38 As discussed
above, the expression of MCP-1 by endothelial cells is pivotal
in recruiting macrophages and other leukocytes into the aneurysm wall. Along these lines, endothelial tight junctions were
found to be disrupted in CAs and were associated with the
migration of leukocytes through endothelial gaps into aneurysm walls.53 Collectively, these data indicate that endothelial
dysfunction, driven by hemodynamic stress, is an early event
in CA physiopathology that initiates and nurtures the inflammatory reaction in arterial walls.

Genetics of CAs
Despite extensive research, relatively little is known about the
genetics of CAs. The role of genetics in CAs may be highlighted by the increased risk of aneurysms and SAH in firstdegree relatives of patients with SAH. As such, CAs are noted
in 2.3% of the general population versus 4% of those with 1
affected first-degree relative and 8% of those with 2 affected
first-degree relatives.54 Some heritable diseases of the connective tissue and extracellular matrix are also associated with an
increased risk of CAs and SAH. Autosomal dominant polycystic kidney disease is the most common heritable disease associated with SAH. CAs may occur in 10% to 13% of patients with
autosomal dominant polycystic kidney disease and in ≤23% of
those >60 years old, but routine screening is not recommended
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in this population.54 Ehlers-Danlos type IV (caused by mutation of collagen type III), fibromuscular dysplasia, and possibly Marfan syndrome (mutation of ﬁbrillin-1 gene) are also
heritable disorders associated with CAs and SAH.54
Whether genetics contribute to CA formation and rupture
is not certain. The largest twin cohort to date, the populationbased Nordic Twin Cohort, which followed 79 644 complete twin pairs of Danish, Finnish, and Swedish origin for
6.01 million person-years did not find a significant degree of
genetic contribution to SAH.55 Based on these data, it might
be tempting to conclude that aneurysmal SAH has little-to-no
genetic basis, and that modifiable risk factors are the major
determinants of SAH risk. In this case, familial CAs would be
attributable to the familial clustering of modifiable risk factors. On the contrary, the powerful genome-wide linkage studies have identiﬁed several genetic loci for CAs, namely 7q11,
14q22, 5q22-31 in a Japanese study and 19q13.3 in a Finnish
study.56 Although no specific gene has been shown thus far to
be associated with CAs, these genetic loci include some promising candidate genes coding for extracellular matrix proteins
such as elastin and collagen. Other candidate genes that have
been studied are those associated with vascular wall formation, matrix degradation, and response of the cerebral artery
to increased stress (including inflammation).56 Among those
genes are lysyl oxidase, fibrillin 2, α1 antitrypsin, MMPs,
tissue inhibitor of metalloproteinase-1, endoglin, angiotensin-converting enzyme, nicotinamide adenine dinucleotide
phosphate-oxidase, p22phox, phospholipase C, endothelial
nitric oxide synthase, transforming growth factor-β receptors,
and polycystin.56 It should be noted that none of the findings of
genetic association studies have been consistently reproducible, and this may be related to the fact that these studies dealt
with different populations and were probably underpowered
to detect a significant genetic association. Large multicenter
studies will be needed to more clearly elucidate the genetic
platform of CAs; however, it is likely that both genetic factors
as well as environmental factors play a role in CA pathogenesis, complicating efforts at disease gene identification.
In clinical practice, genetic approaches may have application in identifying aneurysm-prone patients and rupture-prone
aneurysms or even in controlling aneurysm development and
rupture. Gene therapy, a technique that consists of inserting
a functioning gene into a cell to correct a genetic error or to
introduce a new function may be a potential therapeutic strategy for CAs.57 For example, gene therapy for inhibiting the
overexpression of MMPs, the activation of macrophages, or
the phenotypic modulation of SMCs may theoretically have
efficacy in preventing aneurysm rupture. Unfortunately, however, gene therapies have the best chance of success only if a
specific defective gene is identified, as in cystic fibrosis, for
example. Promoting healing after coil embolization is another
application of gene therapy, and coils carrying antibody-tethered adenovirus may enhance direct gene transfer.57 Candidate
genes are those involved in vascular remodeling and include
growth factors, metalloproteinase inhibitors, and MCP-1.57,58

from 21 countries identified autosomal dominant polycystic kidney disease, a positive family history of CA or SAH,
female sex, and older age as significant risk factors for harboring CAs.59 The meta-analysis did not find a higher prevalence
of CAs in Finnish and Japanese populations, which suggests
that the higher incidence of SAH in those countries60 is related
to higher risks of aneurysm rupture. Smoking and hypertension are 2 well-established risk factors for CAs that were not
included in this meta-analysis.54 However, the same group later
reported in a well-designed case–control study (206 patients
with CAs and 574 controls) that active smoking (odds ratio,
3.0) and hypertension (odds ratio, 2.9) were strong risk factors
for CAs and had an important additive effect (odds ratio, 8.3).61
It is important to note that cigarette smoking may particularly
increase the susceptibility for CA formation in patients with
certain gene variants namely on chromosomes 8q and 9p.62
A recent case–control study found a 10-fold increase in the
prevalence of CAs in patients with bicuspid aortic valve (10%
versus 1.1%).63 An abnormality of cells derived from the neural
crest could explain the association of bicuspid aortic valve with
CAs because the aortic valvular cusps and the media of the
aortic arch and its branches including cervicocephalic arteries are all composed of cells of neural crest origin.63 Patients
with Ehlers-Danlos syndrome type IV, a rare disease caused by
abnormal synthesis of collagen type III, have a structural vascular fragility predisposing to CA formation as well as arterial
dissection and carotid-cavernous fistulas.64 Concerning ethnicity, the risk of harboring an aneurysm seems to be equivalent in
whites, blacks, and Hispanics.65 Finally, regular physical exercise may decrease the risk of harboring an aneurysm.61
It is well known that women are at higher risk of aneurysm
formation, but the female preponderance becomes evident
only in the perimenopausal and postmenopausal periods.60
Indeed, an earlier age at menopause is associated with the
presence of a CA, and hormone replacement therapy protects
against SAH.66,67 Additionally, animal studies have shown a
significant protective role of estrogen against the formation
and progression of CAs.68 The protective role of estrogen is
likely related to its beneficial effects on the inflammatory
reaction in cerebral vessels and the function of endothelial
cells. These effects may involve the inhibition of nuclear
factor-κ B and IL-1β–mediated expression of adhesion molecules, with reduction of adhesion of leukocytes into cerebral
endothelium. Thus, estrogen is undoubtedly one of the numerous therapeutic strategies that may potentially prove efficient
in SAH prevention.
Currently, it is recommended to screen for CAs in patients
with a positive family history. Experts recommend screening
all individuals with 2 affected first-degree relatives because
of the high frequency of CAs in this group.54,69 It may also
be reasonable to screen patients who have 1 affected firstdegree relative if they possess other risk factors for harboring
CAs such as (1) female sex, (2) older age, (3) active smoking,
(4) hypertension, (5) sibling of the affected relative, and (6)
affected relative harbors multiple aneurysms at a young age.

Common Risk Factors for CAs

Common Risk Factors for SAH

There are several risk factors for CAs. A recent, large metaanalysis that included 1450 unruptured CAs in 94 912 patients

The annual rupture rate for CAs is 0.95%, as identified by
the recent well-designed Japanese cohort.70 The same study
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also found that larger aneurysms, aneurysms arising from the
posterior and anterior communicating arteries, and aneurysms
with a daughter sac have higher rates of rupture. Specifically,
the annual rupture rate by location was 0.26% for paraclinoid,
0.67% for middle cerebral artery, 1.31% for anterior communicating, 1.72% for posterior communicating, and 1.90% for
basilar artery aneurysms.70 The annual rupture rate by size was
0.36% for 3 to 4 mm, 0.50% for 5 to 6 mm, 1.67% for 7 to
9 mm, 4.37% for 10 to 24 mm, and 33.4% for giant aneurysms
(≥25 mm). A similar association between size and risk of rupture was observed in the International Study of Unruptured
Intracranial Aneurysms.71 The threshold for treating aneurysms arising from anterior/posterior communicating arteries and the posterior circulation should be lower than that for
other locations. In our experience, most ruptured aneurysms at
those locations tend to be small lesions (≤7 mm).
Besides aneurysm size and location, cigarette smoking is a
strong risk factor for SAH that has been consistently reported
in several studies.72,73 Juvela et al74 recently reported the results
of long-term follow-up (median, 21 years) of 142 patients
with 181 unruptured CAs and found that cigarette smoking in
addition to anterior communicating artery location, decreasing patient age, and aneurysm size ≥7 mm independently predicted aneurysm rupture. Interestingly, a case–control study
reported that smoking may interact with a positive family history of SAH to increase the risk of SAH further than their individual risks.75 Cigarette smoke may lead to CA formation and
rupture through a variety of mechanisms that were recently
reviewed by Chalouhi et al.72 Most of these mechanisms are
related to inflammation. On closer inspection, smoking may
cause hemodynamic stress on arterial walls, induce endothelial dysfunction/apoptosis, promote SMC phenotypic modulation through Kruppel-like transcription factor 4, increase
inflammatory cell infiltration and cytokine release, and most
importantly generate ROS.72 In other terms, cigarette smoke
may affect every step in the cascade of events leading to aneurysm formation, growth, and rupture. Patients harboring CAs
should be strongly counseled to quit smoking especially when
observation is elected. The importance of this simple intervention cannot be overemphasized. Even in those who undergo
embolization, cigarette smoking is a risk factor for aneurysm
recurrence, and patients should also be urged to quit smoking.76 In addition to smoking, hypertension was found to predispose to SAH in prospective population-based follow-up
cohorts.73 Therefore, blood pressure control is another simple
intervention that may help decrease the risk of aneurysm rupture. For some investigators, however, hypertension is a risk
factor for CA formation but does not affect the risk of rupture
once the aneurysm has been formed.
Although heavy alcohol consumption has been shown to
increase the risk of SAH, it does not predispose to aneurysm
formation and growth.54 The increased risk of SAH with alcohol use is likely the result of transient increases in blood pressure. Data from case–control studies suggest that frequent
intake of fat increases the risk of SAH while frequent use of
skim or reduced-fat milk and fruit as well as dietary antioxidants and soy products is protective against SAH.72 Further
studies are needed to confirm these observations. Finally, Vlak
et al77 identified coffee consumption and cola consumption in

addition to anger, startling, straining for defecation, sexual
intercourse, nose blowing, and vigorous physical exercise as
trigger factors for aneurysmal SAH.
Overall, aneurysms ≥7 mm in diameter should be treated
because of their propensity to rupture, except in older patients
and those with significant medical comorbidities and short
life expectancy. Factors that warrant strong consideration for
treatment regardless of the size of the aneurysm include young
patient age, change in the size or configuration of the aneurysm, and the presence of multiple, daughter sac, or symptomatic aneurysms. Factors that may favor intervention over
observation are active smoking, hypertension, posterior circulation aneurysm, anterior/posterior anterior communicating
artery aneurysms, previous SAH, history of familial SAH, and
high aspect ratio.

Aneurysm Geometry and Risk of Rupture
A multitude of geometric indices of CAs have been studied as
possible determinants of rupture risk. Although sophisticated
mathematical models accounting for the 3-dimensional shape
of the aneurysm have been used, only simple indices that can
be calculated in the office setting are most useful in clinical
practice. The aspect ratio defined as CA height divided by
neck diameter is the most studied and perhaps the most useful
shape parameter. In their initial work on aspect ratio, Ujiie
et al78 reported that 80% of ruptured aneurysms had an aspect
ratio of >1.6, whereas 90% of unruptured aneurysms had an
aspect ratio of <1.6. An optimal aspect ratio threshold value,
however, above which CAs may be deemed as dangerous
remains to be determined because different researchers have
reported different thresholds for the aspect ratio. The rationale
behind the aspect ratio is that blood flow is sluggish, and WSS
is low in aneurysms with a high aspect ratio (ie, a large fundus
and a small neck), which as discussed above promotes aneurysm wall remodeling and fragilization. In the clinical setting,
although aspect ratio cannot be relied on as a sole predictor of
aneurysm rupture, an aspect ratio >1.6 should favor intervention over observation in borderline cases.
Another simple and useful geometric index, particularly
suitable for small aneurysms, is the aneurysm-to-vessel size
ratio more commonly referred to as size ratio. In a recent large
study by Kashiwazaki et al79 that included 854 ruptured and
180 unruptured CAs, size ratio strongly correlated with aneurysm rupture and was found to be the only predictive factor for
small CAs rupture. In clinical practice, this means that a 3-mm
aneurysm arising from the anterior communication artery has
a higher risk of rupture than a 3-mm aneurysm of the paraclinoid internal carotid artery.
Hoh et al80 analyzed 30 patients with multiple CAs where
each patient harbored 1 ruptured lesion and ≥1 unruptured
lesions. The authors found that aneurysms with high bottleneck factor were more likely to rupture as were those with a
high height-width ratio (ie, long and thin). Other indices not
covered in this review have also been proposed and showed
some correlation with aneurysm rupture. Overall, because
unruptured aneurysms are being detected with increasing frequency, simple and reliable measurements and indices such
aspect ratio, size ratio, and bottleneck factor may be valuable
to formulate an optimal treatment plan for a given patient.
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Growth of CAs
The growth of a CA is a strong risk factor for future rupture.
As such, many clinicians recommend treating any aneurysm
that has increased in size during the follow-up period. The
approach is justified because the same factors that drive aneurysm growth, namely inflammation and matrix degeneration,
eventually lead to its rupture. This hypothesis is also supported by findings from prospective cohorts. In a recent large
study that followed 258 unruptured aneurysms with computed
tomography angiography, the annual risk of rupture was
found to be 2.4% in aneurysms with growth versus only 0.2%
in those without growth (ie, 12-fold increase in risk of rupture).81 The risk of aneurysm growth itself was associated with
tobacco smoking and initial size. The authors concluded that
aneurysm growth was not uncommon, and that all incidental
aneurysms require longitudinal follow-up imaging to monitor
for possible growth, including small lesions.81
An aneurysm grows either by expansion of the wall because
of proliferation of mural cells with production of extracellular
matrix and myointimal hyperplasia, or by distension attributable to hemodynamic pressure in degenerated CAs, or most
commonly by a combination of these 2 mechanisms.82 The
inflammatory reaction is a major factor in this process because
it drives both mural cell growth with extracellular matrix
production and degeneration of the aneurysm wall. Indeed,
inhibition of nuclear factor-κ B, ROS, MMPs/cathepsin, and
MCP-1 was shown to decrease aneurysm growth.3 Mitogenactivated protein kinases, a family of intracellular signaling
proteins that have a critical role in cell growth, proliferation, differentiation, and apoptosis, have also been shown to
be actively involved in aneurysm growth. Specifically, the
proapoptotic p54 Jun N-terminal kinase and the proinflammatory p38 seem to be closely associated with CA growth,
although the involved pathways remain poorly understood.83
Overall, the mechanisms underlying CA growth seem to be
complex. Although, most CAs will grow before rupturing,
many aneurysms will not. This may suggest that the processes driving aneurysm progression and rupture may not be
entirely identical.
In patients managed conservatively, periodic follow-up
(every 6–12 months) with noninvasive imaging studies (magnetic resonance angiography or computed tomography angiography) is recommended. Strong consideration for treatment
should be given to any aneurysm that grows over the followup period because this suggests active inflammatory processes
in the aneurysm wall.

Targeted Imaging of Inflammation: the Emerging
Role of Ferumoxytol-Enhanced MRI
Targeted imaging of inflammatory cells and molecules
involved in CA pathogenesis is an interesting strategy that
may provide important information on the natural history of
these lesions. Ferumoxytol-enhanced MRI is one such technique that is recently being investigated. Ferumoxytol is a
member of the class of nanoparticles known as ultrasmall
superparamagnetic iron oxide and is approved by the Food
and Drug Administration as a treatment for iron deficiency
anemia in patients with chronic renal failure. It also is useful

as an intravascular contrast agent and an inflammatory marker
when imaging is delayed because it is cleared by macrophages
(usually within 24–72 hours). Hasan et al9,35,84 have investigated the possibility of using ferumoxytol-enhanced MRI for
noninvasive assessment of the inflammatory status of CAs
through the detection of the activity of macrophages. In their
initial work, they found that the optimal technique for imaging macrophages in human CA walls is infusion of 5 mg/kg of
ferumoxytol and imaging at 72 hours after injection.10 Later,
they demonstrated that the findings of ferumoxytol-enhanced
MRI may well predict the risk of aneurysm rupture.9 Combing
radiological and histological findings, they found that CAs
with early uptake of ferumoxytol (at 24 hours) exhibited more
intense inflammation in their walls and had a higher risk of
rupture than aneurysms with no or only late uptake of ferumoxytol (at 72 hours).9 Thus, if validated in larger studies,
the technique may allow physicians to differentiate unstable
aneurysms that require intervention from stable aneurysms
where observation is appropriate. Specifically, this technique
could prove particularly useful in identifying rupture-prone
aneurysms in patients that often pose a therapeutic dilemma,
namely elderly patients (>70 years old) and patients harboring small aneurysms (<5–7 mm). Moreover, ferumoxytolenhanced MRI may allow noninvasive monitoring of the effects
of anti-inflammatory pharmacological interventions (such as
ASA) on CAs.35,84 As discussed above, if aspirin is adopted
as a therapy for CAs, the technique may be used to identify
those who respond to medical treatment versus those who will
require more invasive treatment. Future improvements in technique and MRI signal quantification may allow efficient use of
ferumoxytol-enhanced MRI in clinical practice.

Conclusions
Inflammation plays a central role in the pathogenesis of CAs.
The common pathway for CA formation, growth, and rupture
includes initially an endothelial dysfunction induced by hemodynamic stress, followed by an inflammatory reaction in arterial
walls involving primarily macrophages and SMCs, and finally a
degradation of the extracellular matrix by MMPs, which paves
the way for aneurysm rupture. Knowledge of these mechanisms
has allowed the conception of promising molecular-based imaging studies identifying rupture-prone CAs. Pharmacological
therapy targeting the inflammatory reaction is also being
investigated as a potential therapeutic strategy for CAs. Future
experimental studies and clinical trials will be needed to further
deepen our knowledge of this complex disease and to provide
patients with efficient and innocuous therapies.
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